// App-Quantinova.ai

1402 : Exploratory biomarkers that predict for clinical outcomes in a Phase II trial with ipilimumab plus finite androgen deprivation therapy for metastatic non-castrate prostate cancer

Researchers

Presenter

  • Sumit K. Subudhi

Principal Investigators

  • Ana Aparicio

  • Jianjun Gao

  • Amado Zurita-Saavedra

  • John C. Araujo

  • Christopher J. Logothetis

  • Korivi R. Brinda

  • Jim P. Allison

  • Luis Vence

  • Ryan O. Emerson

  • Erik Yusko

  • Marissa Vignali

  • Harlan S. Robins

  • Jingjing Sun

  • Padmanee Sharma

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Adapative Biotechnologies Corporation, TX.

Locations

  • United States

Companies

  • Adaptive Biotechnolo

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Ipilimumab

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Single Center

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved